The Food and Drug Administration’s (FDA) authority to regulate lab-developed tests, known as LDTs, is preparing to face legal battles and compliance obstacles. Concerns are rising from industry members about the FDA’s latitude and its potential impact on innovation.
The FDA’s ruling provides explicit control over certain medical tests that come from single laboratories. Published in the Federal Register on May 6th, this 160-page rule clarifies that in vitro diagnostics (IVDs) encompass tests manufactured by a laboratory under the Federal Food, Drug, and Cosmetic Act. Alongside this clarification, a timeline for a five-stage phaseout plan over a four-year period has been outlined.
However, not all diagnostics are included under the regulation. The decree carves out certain tests, exempting them from full examination. This exception has become a source of apprehension for some industry factions. They fear these exceptions could result in regulatory uncertainties, bringing along unfamiliar compliance hurdles.
There is also worry within the industry that supervision by the FDA could hamper innovation. Many industry groups argue that genetic tests, which have traditionally been developed by experienced and accredited diagnostic labs, could potentially be stifled by the increased oversight.
Legal debates concerning the FDA’s authority over LDTs have been ongoing for some time. Indeed, the situation is likely to escalate into concrete litigation as the rule begins to take effect and the four-year phaseout period progresses, always bearing risks and implications for corporations and law firms alike.
For more detailed information, the full article with these insights can be found on Bloomberg Law.